Oncotarget

Research Papers:

CD73 is associated with poor prognosis in HNSCC

Zhen-Hu Ren, Cheng-Zhong Lin, Wei Cao, Rong Yang, Wei Lu, Zhe-Qi Liu, Yi-Ming Chen, Xi Yang, Zhen Tian, Li-Zhen Wang, Jiang Li, Xu Wang, Wan-Tao Chen, Tong Ji and Chen-Ping Zhang _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2016; 7:61690-61702. https://doi.org/10.18632/oncotarget.11435

Metrics: PDF 2427 views  |   HTML 5755 views  |   ?  


Abstract

Zhen-Hu Ren1,2,*, Cheng-Zhong Lin1,2,*, Wei Cao1,2, Rong Yang1,2, Wei Lu1,2, Zhe-Qi Liu1,2, Yi-Ming Chen1,2, Xi Yang1,2, Zhen Tian3, Li-Zhen Wang3, Jiang Li3, Xu Wang1,2, Wan-Tao Chen1,2, Tong Ji1,2, Chen-Ping Zhang1,2

1Department of Oral Maxillofacial-Head and Neck Oncology, Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200011, China

2Shanghai Research Institute of Stomatology and Shanghai Key Laboratory of Stomatology, Shanghai 200011, China

3Department of Oral Pathology, Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200011, China

*These authors contributed equally to this work

Correspondence to:

Chen-Ping Zhang, email: [email protected]

Tong Ji, email: [email protected]

Keywords: CD73, adenosine receptor, EGFR, EMT, head and neck squamous cell carcinoma

Received: April 18, 2016     Accepted: July 28, 2016     Published: August 20, 2016

ABSTRACT

CD73 is a cell surface immunosuppressive enzyme involved in tumor progression and metastasis. While patients whose cancer cells express elevated CD73 are typically associated with an unfavorable outcome, the clinical impact of CD73 expression in patients with Head and neck squamous cell carcinoma (HNSCC) remains unclear. In the present study, we investigated the prognostic significance of CD73 in HNSCC using gene and protein expression analyses. Our results demonstrate that high levels of CD73 are significantly associated with reduced overall survival in patients with HNSCC. We also investigated the functional role of CD73 in vitro and demonstrated that CD73 promotes HNSCC migration and invasion through adenosine A3R stimulation and the activation of EGF/EGFR signaling. Moreover, in vivo xenograft studies demonstrated that CD73 promotes tumorigenesis. In conclusion, our study highlights a role for CD73 as a poor prognostic marker of patient survival and also as a candidate therapeutic target in HNSCCs.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 11435